Abstract | OBJECTIVE: METHODS: A total of 240 patients were randomized to either a tirofiban group or a control group. RESULTS: Compared with the control group, the platelet aggregation rate in the tirofiban group was lower (P < 0.01); the plasma levels of CK-MB and troponin I, cardiac form (cTnI) were lower (P < 0.05); ECG improved significantly (P < 0.05); the incidence of major adverse cardiac events ( MACE) was lower (P < 0.05); and there was no difference in bleeding complications between the 2 groups (P = 0.1). CONCLUSIONS: The administration of tirofiban in high risk patients with NSTE-ACS after PCI is safe and effective.
|
Authors | Zhenxian Yan, Yujie Zhou, Yingxin Zhao, Yueping Li, Xiaomin Nie, Zhiming Zhou, Dean Jia |
Journal | Clinical cardiology
(Clin Cardiol)
Vol. 32
Issue 9
Pg. E40-4
(Sep 2009)
ISSN: 1932-8737 [Electronic] United States |
PMID | 19645039
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Copyright | Copyright 2009 Wiley Periodicals, Inc. |
Chemical References |
- Biomarkers
- Platelet Aggregation Inhibitors
- Troponin I
- Tyrosine
- Creatine Kinase, MB Form
- Tirofiban
|
Topics |
- Acute Coronary Syndrome
(drug therapy, mortality, therapy)
- Aged
- Angioplasty, Balloon, Coronary
(adverse effects, mortality)
- Biomarkers
(blood)
- Creatine Kinase, MB Form
(blood)
- Double-Blind Method
- Electrocardiography
- Female
- Heart Diseases
(blood, etiology, mortality, prevention & control)
- Hemorrhage
(chemically induced)
- Humans
- Male
- Middle Aged
- Platelet Aggregation
(drug effects)
- Platelet Aggregation Inhibitors
(adverse effects, therapeutic use)
- Prospective Studies
- Risk Assessment
- Thrombocytopenia
(chemically induced)
- Time Factors
- Tirofiban
- Treatment Outcome
- Troponin I
(blood)
- Tyrosine
(adverse effects, analogs & derivatives, therapeutic use)
|